Integrating immune-driven models, including IL-10 knockout and T-cell transfer approaches, would enhance preclinical applicability, providing more comprehensive platforms to elucidate IBD pathogenesis and assess novel therapeutic interventions. Here, IL10 is linked to inflammatory bowel disease.